BRONCUS-B (02216) Announces Interim Results: Adjusted Net Loss Widens 14.7% to $7.98 Million
Stock News
Aug 27
Chinese medical device firm BRONCUS-B (02216) has unveiled its financial performance for the six-month period ended June 30, 2026, revealing a notable surge in revenue alongside a widening adjusted loss.
The company recorded revenue of $3.29 million for the interim period, marking a substantial 99% year-on-year increase. Meanwhile, the adjusted net loss stood at $7.98 million, reflecting a 14.7% expansion compared to the prior corresponding period. The loss per share was reported at $0.02.
According to the official announcement, the revenue growth was primarily driven by the Chinese market, where both equipment and consumables segments delivered year-on-year increases during the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.